Sean E. Aeder

Array ( [id] => 15210611 [patent_doc_number] => 20190367992 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-05 [patent_title] => RESISTANCE TO CHECKPOINT BLOCKADE THERAPY [patent_app_type] => utility [patent_app_number] => 16/477827 [patent_app_country] => US [patent_app_date] => 2018-01-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13451 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -45 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16477827 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17280915 [patent_doc_number] => 11197928 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-12-14 [patent_title] => Sustained production of high affinity antigen specific antibody by high dose BAFF receptor-targeting mAb-siRNA conjugate [patent_app_type] => utility [patent_app_number] => 15/868912 [patent_app_country] => US [patent_app_date] => 2018-01-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 21 [patent_no_of_words] => 14318 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 89 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15868912 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17713713 [patent_doc_number] => 11377697 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-07-05 [patent_title] => Biomarkers predictive of anti-immune checkpoint response [patent_app_type] => utility [patent_app_number] => 16/475577 [patent_app_country] => US [patent_app_date] => 2018-01-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 22 [patent_no_of_words] => 72893 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 179 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16475577 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18274850 [patent_doc_number] => 11613785 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-03-28 [patent_title] => Predictive and diagnostic methods for prostate cancer [patent_app_type] => utility [patent_app_number] => 16/476420 [patent_app_country] => US [patent_app_date] => 2018-01-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 19722 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16476420 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12912625 [patent_doc_number] => 20180196051 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-12 [patent_title] => Phosphoproteins in Extracellular Vehicles as Candidate Markers for Breast Cancer [patent_app_type] => utility [patent_app_number] => 15/864376 [patent_app_country] => US [patent_app_date] => 2018-01-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7113 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15864376 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17713712 [patent_doc_number] => 11377696 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-07-05 [patent_title] => PBRM1 biomarkers predictive of anti-immune checkpoint response [patent_app_type] => utility [patent_app_number] => 16/475574 [patent_app_country] => US [patent_app_date] => 2018-01-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 37 [patent_figures_cnt] => 24 [patent_no_of_words] => 91199 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 147 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16475574 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12842500 [patent_doc_number] => 20180172673 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-21 [patent_title] => PROFILING PEPTIDES AND METHODS FOR SENSITIVITY PROFILING [patent_app_type] => utility [patent_app_number] => 15/847697 [patent_app_country] => US [patent_app_date] => 2017-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28591 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15847697 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15088951 [patent_doc_number] => 20190339286 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-07 [patent_title] => METHOD TO DETERMINE BRAF MUTATIONS AND WILD TYPE BRAF PROTEIN BY MASS SPECTROMETRY [patent_app_type] => utility [patent_app_number] => 16/470551 [patent_app_country] => US [patent_app_date] => 2017-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10561 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 158 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16470551 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15041325 [patent_doc_number] => 20190331667 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-31 [patent_title] => CIRCULATING SURVIVIN-POSITIVE EXOSOMES [patent_app_type] => utility [patent_app_number] => 16/470197 [patent_app_country] => US [patent_app_date] => 2017-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5427 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16470197 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16016067 [patent_doc_number] => 20200182876 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-11 [patent_title] => METHODS FOR THE DETECTION AND TREATMENT OF PANCREATIC DUCTAL ADENOCARCINOMA [patent_app_type] => utility [patent_app_number] => 16/469065 [patent_app_country] => US [patent_app_date] => 2017-12-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22352 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16469065 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13566347 [patent_doc_number] => 20180334721 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-22 [patent_title] => METHODS FOR THE DIAGNOSIS OF ONCOLOGICAL DISORDERS USING EPIMETABOLIC SHIFTERS, MULTIDIMENSIONAL INTRACELLULAR MOLECULES, OR ENVIRONMENTAL INFLUENCERS [patent_app_type] => utility [patent_app_number] => 15/841972 [patent_app_country] => US [patent_app_date] => 2017-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 74508 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15841972 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12909871 [patent_doc_number] => 20180195133 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-12 [patent_title] => METHODS AND BIOMARKERS FOR PREDICTING EFFICACY AND EVALUATION OF AN OX40 AGONIST TREATMENT [patent_app_type] => utility [patent_app_number] => 15/836729 [patent_app_country] => US [patent_app_date] => 2017-12-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51380 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15836729 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12676030 [patent_doc_number] => 20180117176 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-03 [patent_title] => POROUS SILICON MICROPARTICLE-BASED CANCER VACCINES AND METHODS FOR POTENTIATING ANTI-TUMOR IMMUNITY [patent_app_type] => utility [patent_app_number] => 15/832771 [patent_app_country] => US [patent_app_date] => 2017-12-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18673 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15832771 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13165717 [patent_doc_number] => 10098951 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-10-16 [patent_title] => Antibody/T-cell receptor chimeric constructs and uses thereof [patent_app_type] => utility [patent_app_number] => 15/829793 [patent_app_country] => US [patent_app_date] => 2017-12-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 54 [patent_figures_cnt] => 68 [patent_no_of_words] => 90313 [patent_no_of_claims] => 46 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 240 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15829793 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12786460 [patent_doc_number] => 20180153989 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-07 [patent_title] => COMPOSITIONS AND METHODS RELATED TO CELL SYSTEMS FOR PENETRATING SOLID TUMORS [patent_app_type] => utility [patent_app_number] => 15/829678 [patent_app_country] => US [patent_app_date] => 2017-12-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31099 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15829678 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14994507 [patent_doc_number] => 20190316211 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-17 [patent_title] => ONCOGENIC ALTERNATIVE SPLICING SWITCH OF PACE4 IN CANCER [patent_app_type] => utility [patent_app_number] => 16/463476 [patent_app_country] => US [patent_app_date] => 2017-11-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16579 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16463476 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12746536 [patent_doc_number] => 20180140679 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-24 [patent_title] => MODULATION OF AXL RECEPTOR ACTIVITY IN COMBINATION WITH CYTOREDUCTIVE THERAPY [patent_app_type] => utility [patent_app_number] => 15/818251 [patent_app_country] => US [patent_app_date] => 2017-11-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19739 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15818251 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12728893 [patent_doc_number] => 20180134798 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-17 [patent_title] => DOSING FOR TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES [patent_app_type] => utility [patent_app_number] => 15/813657 [patent_app_country] => US [patent_app_date] => 2017-11-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29674 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -68 [patent_words_short_claim] => 152 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15813657 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17267547 [patent_doc_number] => 11192959 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-12-07 [patent_title] => Antibody binding to carbonic anhydrase and use thereof [patent_app_type] => utility [patent_app_number] => 16/347254 [patent_app_country] => US [patent_app_date] => 2017-11-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 36 [patent_figures_cnt] => 40 [patent_no_of_words] => 20936 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 97 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16347254 [rel_patent_id] =>[rel_patent_doc_number] =>)